From Name

From Email

To Name

To Email

Message

Critical recurring mutation identified in head and neck cancers

from Genetic Engineering & Biotechnology News

Critical recurring mutation identified in head and neck cancers Genetic Engineering & Biotechnology News Scientists at the University of California-San Diego report that an investigational drug candidate called tipifarnib showed promise in treating head and neck squamous cell carcinoma tumors with mutations in the HRAS gene. Head and neck cancer is one of the leading causes of cancer-related deaths worldwide, and squamous cell carcinomas account for the majority of these cases. READ MORE

more